Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
Key Highlights Implications: Lormalzi gives Lilly an early foothold in India’s tiny but fast‑growing market for disease‑modifying Alzheimer’s drugs, while it test...
Key Highlights: Implications: Wockhardt’s SEC nod for Zaynich marks a major step toward India’s first home-grown, dual‑mechanism anti‑Gram‑negative launched in the carbapenem‑resistan...
Key Highlights: Implications: By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiatio...
Key Highlights: Implications: Qdenga’s positive SEC opinion moves India close to its first widely available dengue vaccine, with import approval tied to a rapid post‑marketing s...
Key Highlights: Implications: This curbs aggressive GLP-1 marketing (e.g., Ozempic/Wegovy), protecting India’s $115M diabetes/obesity segment from off-label hype amid 101M diabetics....
